l-Aminoacyl-triazine Derivatives Are Isoform-Selective PI3Kβ Inhibitors That Target Nonconserved Asp862 of PI3Kβ

作者: Jo-Anne Pinson , Zhaohua Zheng , Michelle S. Miller , David K. Chalmers , Ian G. Jennings

DOI: 10.1021/ML300336J

关键词: Akt phosphorylationStereochemistryMutantResidue (chemistry)Gene isoformPharmacologySelectivityChemistryTriazine

摘要: A series of aminoacyl-triazine derivatives based upon the pan-PI3K inhibitor ZSTK474 were identified as potent and isoform-selective inhibitors PI3Kβ. The compounds showed selectivity stereochemistry with l-amino acyl preferring PI3Kβ, while their d-congeners favored PI3Kδ. mechanistic basis this inhibition was studied using site-directed mutants. One Asp residue, D862, a critical participant in binding to PI3Kβ-selective inhibitors, distinguishing class from other reported inhibitors. show strong cellular Akt phosphorylation growth PTEN-deficient MD-MBA-468 cells.

参考文章(29)
S. NYLANDER, B. KULL, J. A. BJÖRKMAN, J. C. ULVINGE, N. OAKES, B. M. EMANUELSSON, M. ANDERSSON, T. SKÄRBY, T. INGHARDT, O. FJELLSTRÖM, D. GUSTAFSSON, Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. Journal of Thrombosis and Haemostasis. ,vol. 10, pp. 2127- 2136 ,(2012) , 10.1111/J.1538-7836.2012.04898.X
Jorge J Castillo, Michael Furman, Eric S Winer, CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs. ,vol. 21, pp. 15- 22 ,(2012) , 10.1517/13543784.2012.640318
Montserrat Camps, Thomas Rückle, Hong Ji, Vittoria Ardissone, Felix Rintelen, Jeffrey Shaw, Chiara Ferrandi, Christian Chabert, Corine Gillieron, Bernard Françon, Thierry Martin, Denise Gretener, Dominique Perrin, Didier Leroy, Pierre-Alain Vitte, Emilio Hirsch, Matthias P Wymann, Rocco Cirillo, Matthias K Schwarz, Christian Rommel, Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis Nature Medicine. ,vol. 11, pp. 936- 943 ,(2005) , 10.1038/NM1284
Xuxiao Zhang, Oscar Vadas, Olga Perisic, Karen E. Anderson, Jonathan Clark, Phillip T. Hawkins, Len R. Stephens, Roger L. Williams, Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism Molecular Cell. ,vol. 41, pp. 567- 578 ,(2011) , 10.1016/J.MOLCEL.2011.01.026
Hong Lin, Karl Erhard, Mary Ann Hardwicke, Juan I. Luengo, James F. Mack, Jeanelle McSurdy-Freed, Ramona Plant, Kaushik Raha, Cynthia M. Rominger, Robert M. Sanchez, Michael D. Schaber, Mark J. Schulz, Michael D. Spengler, Rosanna Tedesco, Ren Xie, Jin J. Zeng, Ralph A. Rivero, Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors Bioorganic & Medicinal Chemistry Letters. ,vol. 22, pp. 2230- 2234 ,(2012) , 10.1016/J.BMCL.2012.01.092
Hong Lin, Mark J. Schulz, Ren Xie, Jin Zeng, Juan I. Luengo, Michael D. Squire, Rosanna Tedesco, Junya Qu, Karl Erhard, James F. Mack, Kaushik Raha, Ramona Plant, Cynthia M. Rominger, Jennifer L. Ariazi, Christian S. Sherk, Michael D. Schaber, Jeanelle McSurdy-Freed, Michael D. Spengler, Charles B. Davis, Mary Ann Hardwicke, Ralph A. Rivero, Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors ACS Medicinal Chemistry Letters. ,vol. 3, pp. 524- 529 ,(2012) , 10.1021/ML300045B
Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, Raphael Frederick, William A Denny, Bruce C Baguley, Philip Kestell, Ripudaman Singh, Jackie D Kendall, Elaine S Marshall, Claire L Lill, Woo-Jeong Lee, Sharada Kolekar, Christina M Buchanan, Stephen MF Jamieson, Peter R Shepherd, None, Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Journal of Medicinal Chemistry. ,vol. 54, pp. 7105- 7126 ,(2011) , 10.1021/JM200688Y
S. J. Shuttleworth, F. A. Silva, A. R.L. Cecil, C. D. Tomassi, T. J. Hill, F. I. Raynaud, P. A. Clarke, P. Workman, Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors Current Medicinal Chemistry. ,vol. 18, pp. 2686- 2714 ,(2011) , 10.2174/092986711796011229
Kevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman, The PI3K Pathway As Drug Target in Human Cancer Journal of Clinical Oncology. ,vol. 28, pp. 1075- 1083 ,(2010) , 10.1200/JCO.2009.25.3641
Michael L. Moore, Hongyi Yu, Juan I. Luengo, Rosanna Tedesco, Ralph A. Rivero, Robert M. Sanchez, Karl Erhard, Mary Ann Hardwicke, Hong Lin, Jeanelle McSurdy-Freed, Ramona Plant, Kaushik Raha, Cynthia M. Rominger, Michael D. Schaber, Michael D. Spengler, Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors Bioorganic & Medicinal Chemistry Letters. ,vol. 22, pp. 3198- 3202 ,(2012) , 10.1016/J.BMCL.2012.03.039